Loading...
Loading...
Browse all stories on DeepNewz
VisitFDA Approves Amgen's Interchangeable Biosimilar to AstraZeneca's Soliris on Tuesday
May 28, 2024, 10:30 PM
The U.S. Food and Drug Administration (FDA) has approved Amgen's Bkemv, the first interchangeable biosimilar to AstraZeneca's Soliris, a treatment for rare blood disorders. Bkemv is approved for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis and atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. This approval, announced on Tuesday, marks a significant milestone in the availability of biosimilar treatments for rare diseases.
View original story
Markets
Yes • 50%
No • 50%
FDA official announcements or credible healthcare news sources
Yes • 50%
No • 50%
AstraZeneca's press releases or major healthcare news outlets
Yes • 50%
No • 50%
Amgen's annual financial report or credible market analysis reports
Stock price increases • 33%
Stock price decreases • 33%
Stock price remains stable • 34%
Financial news outlets and stock analysis
Other competitors gain significant market share • 34%
Amgen's Bkemv dominates • 33%
AstraZeneca retains majority market share • 33%
Market research reports or analysis from credible healthcare research firms
No new approvals • 25%
1 new approval • 25%
2 new approvals • 25%
3 or more new approvals • 25%
FDA official announcements or healthcare regulatory updates